Douro Biologics Douro Biologics
Precision Antibody Engineering

Application-validated recombinant antibodies.

Full-stack antibody engineering — from in silico design to purified, application-validated protein — out of a lean fab in Portugal. Built for specificity and reproducibility, not cost-per-gram.

Partner with us See what we do
Scroll
The problem

Most research antibodies can't be trusted.

50%+
Over half of research antibodies fail validation in at least one application. Irreproducible reagents waste budgets and retract conclusions. Our answer: affordable, recombinant, application-validated antibodies with knockout controls. Source: Ayoubi et al., YCharOS, eLife 2023.
What we do

Full-stack, under one roof.

In silico design and engineering combined with in-house production, purification and application validation — solely recombinant antibodies, no other protein classes.

In silico design

Sequence- and structure-guided design; affinity and specificity engineering.

Recombinant production

Mammalian expression and downstream purification, with QC built into the process.

Application validation

Knockout-controlled validation across every key assay.

WBIFICCIHCFACSIP

Analytics

BLI binding assays and flow cytometry on demand.

Why Douro

We compete on quality, specificity and reproducibility.

The research-use game is won on trust, not tonnage. A small footprint with high yield per litre lets us obsess over every clone.

Full-stack in one lab

Design to validated protein, no hand-offs between vendors.

Knockout-controlled validation

Every antibody proven specific against the right controls.

Lean, high-yield fab

Bioreactors up to 15 L — deliberately small-scale and high-yield.

A real point of contact

One dedicated contact per client, same-day response, per-project reporting.

The opportunity

A large, growing reagents market — with a reproducibility gap to close.

Portugal-based, with Oxford and global connections. Serving research labs across Portugal and Europe, extending to the US and China.

$4–6B → $8–11B
Research antibodies market, 2025 → 2030 (~7–9% CAGR).
$17–18B → $24B
Wider antibodies & reagents market, 2025 → 2030 (~7% CAGR).
IVD
Natural adjacency into diagnostics as validated reagents mature.

To be the best antibody engineers there is — the go-to lab for high-quality, application-validated recombinant antibodies.

Investment & partnership

Let's build the reproducibility standard.

We're raising to build our antibody production lab and expand capacity. If you invest in or partner with early-stage life-science ventures, we'd like to talk.

Get in touch